Teachers Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Teachers Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-213	Closed	-$20K	–	3013
2017 Q4	$20K	Hold	213	–	–	﹤0.01%	3058
2017 Q3	$32K	Hold	213	–	–	﹤0.01%	3062
2017 Q2	$22K	Buy	+213	New	+$24.2K	﹤0.01%	3103
2016 Q2	–	Sell	-202	Closed	-$19K	–	3149
2016 Q1	$19K	Buy	+202	New	+$17.9K	﹤0.01%	3038

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Teachers Advisors's IMDX Position: Q1 2018 in Review

Teachers Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q1 2018, closing a stake of 213 shares — an estimated $20K sold.

Teachers Advisors first reported a position in IMDX in Q1 2016 and held it in 4 quarters. The position peaked at $32K in Q3 2017. 39 funds tracked by Wall St. Rank hold IMDX as of Q1 2018.

Teachers Advisors reported no remaining Insight Molecular Diagnostics position as of Q1 2018 after selling out during the quarter.
Teachers Advisors sold 213 Insight Molecular Diagnostics shares in Q1 2018, an estimated $20K.
Teachers Advisors first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 4 quarters.
Teachers Advisors's Insight Molecular Diagnostics position peaked at $32K in Q3 2017.
39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2018.

Based on Teachers Advisors's 13F filing for Q1 2018, filed 14 May 2018.